145
Participants
Start Date
November 19, 2021
Primary Completion Date
August 5, 2024
Study Completion Date
February 15, 2029
Selumetinib
Selumetinib oral capsules (10 mg and 25 mg)
Placebo
Placebo oral capsules for Selumetinib masking (10 mg and 25 mg)
Research Site, St Leonards
Research Site, Melbourne
Research Site, Commack
Research Site, Milan
Research Site, Hamburg
Research Site, Rockville
Research Site, Madrid
Research Site, Toulouse
Research Site, Gainesville
Research Site, St Louis
Research Site, Lyon
Research Site, Tübingen
Research Site, Napoli
Research Site, Créteil
Research Site, Würzburg
Research Site, Beijing
Research Site, Beijing
Research Site, Shenyang
Research Site, Moscow
Research Site, Moscow
Research Site, Guangzhou
Research Site, Porto Alegre
Research Site, Ribeirão Preto
Research Site, São Paulo
Research Site, Toronto
Research Site, Montreal
Research Site, Roma
Research Site, Minatoku
Research Site, Nagoya
Research Site, Shinjuku-ku
Research Site, Bydgoszcz
Research Site, Badalona
Research Site, London
Research Site, Manchester
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
AstraZeneca
INDUSTRY